Goldman Sachs
GEVA

Goldman Sachs’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Goldman Sachs’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-35,900
Closed -$3.33M – 7509
2014
Q4 		$3.33M Buy
+35,900
New +$2.83M ﹤0.01% 3363
2014
Q3 		– Sell
-30,000
Closed -$3.14M – 7450
2014
Q2 		$3.14M Buy
+30,000
New +$2.55M ﹤0.01% 3524

Goldman Sachs's GEVA Position: Q2 2015 in Review

Goldman Sachs sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 114,476 shares — an estimated $11.2M sold.

Goldman Sachs first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $13M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Goldman Sachs reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Goldman Sachs sold 114,476 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $11.2M.
  • Goldman Sachs first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Goldman Sachs's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $13M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Goldman Sachs's 13F filing for Q2 2015, filed 14 Aug 2015.